State-Level Substitution Rules for Biosimilars
February 7th 2013Legislators in at least 10 states are rushing to introduce pharmacy law that would govern the use of biosimilar substitution-but without further FDA guidance on interchangeability, physicians may be less likely to switch patients to lower-cost alternatives.
Read More
AMCP Revises Formulary Document to Reflect New Recommendations for Specialty Pharmaceuticals
January 29th 2013Updates to this invaluable industry guide include new portions pertaining to specialty pharmaceuticals, comparative effectiveness research, and companion diagnostics tests, as well as a new definition for the term "specialty pharmacy."
Read More
FDA Grants First Breakthrough Therapy Designations to Cystic Fibrosis Drugs
January 15th 2013The Breakthrough Therapy initiative, which is part of the 2012 Food and Drug Administration Safety and Innovation Act, will bring promising treatments more quickly through an expedited review process.
Read More
Elderly Myeloma Patients Benefit from Lower-Dose Drug Regimen, Addition of Velcade
January 10th 2013A new study revealed that lower doses of Velcade (bortezomib), melphalan (Alkeran) and prednisone (VMP) was effective and safe in extending overall and progression-free survival in older patients.
Read More
Building a Computer Model of Myeloma
January 10th 2013Representatives from The Dana –Farber Cancer Institute, Mount Sinai, and GNS Healthcare recently announced they are teaming up to pool their data and technology assets in order to build a predictive model of multiple myeloma disease progression.
Read More
Medicare Could Have Saved $33 Million on Prostate Cancer Drugs
November 28th 2012By prescribing clinically similar luteinizing hormone–releasing hormone agonists for the treatment of prostate cancer, Medicare could have saved 13% of its total budget for monthly injections, according to a study from the Office of the Inspector General.
Read More
Specialty Pharmacy Services Produce Better Health Outcomes for RA Patients
November 28th 2012In a retrospective analysis, researchers concluded that rheumatoid arthritis patients had better outcomes when they filled their prescriptions through a mail-order specialty pharmacy rather than a retail pharmacy.
Read More
Specialty Products: BriovaRx's Holistic Approach
November 28th 2012In an exclusive interview with Specialty Pharmacy Times, Albert Thigpen, Senior Vice President of Pharmacy Operations & Industry Relations at Catamaran Corporation, spoke about his distinct responsibilities surrounding the management of pharmaceutical manufacturers, Catamaran's 3 mail order pharmacies, and BriovaRx's 11 specialty pharmacies.
Read More
Higher Copays for Multiple Sclerosis Medications Contribute to Poor Patient Compliance, Outcomes
November 22nd 2012A recent study featured in the American Journal of Pharmacy Benefits examines the role of patient out-of-pocket cost on adherence to disease-modifying therapies for multiple sclerosis.
Read More
Xeljanz: Juggling a Delicate Risk-Benefit Ratio
November 16th 2012Pfizer's Xeljanz (tofacitinib) is the first Janus kinase inhibitor approved for rheumatoid arthritis and the first oral biologic within the RA class. Dina Rufo of GlobalData discusses the factors that will affect uptake of the drug.
Read More
CSPN Signs Distribution Agreement with Dara BioSciences
November 16th 2012Community Specialty Pharmacy Network, Inc (CSPN), recently announced a distribution agreement with Dara BioSciences for Soltamox (tamoxifen citrate), a nonsteroidal antiestrogen for the treatment of patients with breast cancer.
Read More